Vincerx Pharma, Inc. (VINC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.4500 |
| Open | 1.4700 |
| Bid | 1.3200 x 4000 |
| Ask | 1.3500 x 1000 |
| Day's Range | 1.3100 - 1.5400 |
| 52 Week Range | 1.2600 - 18.4270 |
| Volume | |
| Avg. Volume | 160,975 |
| Market Cap | 27.748M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6530 |
| Earnings Date | Nov 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- GlobeNewswire
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity, target modulation, early signs of clinical efficacy, and cardiac safety in lymphoma patients treated with VIP152 PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer throu
- Benzinga
Analysts Cuts Price Target On This Small Cap But Remain Bullish
Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares. The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse large B-cell lymphoma and chronic lymphocytic leukemia. It also implemented a 33% workforce reduction and other cost reduction measures due to "unprecedented market conditions." The analyst updated his model to reflect a narrower de
- Benzinga
Small Cap Biotech Vincerx Cuts Third Of Staff
Cancer-focused biotech Vincerx Pharma Inc (NASDAQ: VINC) would lay off 33% of its staff to get its lead program through two Phase I studies. The move comes a little less than two years after Vincerx went public via a SPAC and its stock fell more than 80% in 2022. “Reducing our staff was not an easy decision,” CEO Ahmed Hamdy said. “It was the tremendous effort of our Vincerx colleagues that allowed us to execute efficiently, despite the extreme pressures of the pandemic.” Vincerx said it is prio
